Skip to main content

Advertisement

Table 3 Ongoing asthma therapies concomitant to omalizumab during the observational period by gender

From: Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study

Treatment regimen Females (N = 54) n (%) Males (N = 34) n (%) p-value*
No ongoing therapies 1 (1.9) 0 (0.0) 0.281
ICS 43 (79.6) 31 (91.2)  
 ICS only 3 (5.6) 3 (8.8)  
 ICS/LABA only 33 (61.1) 21 (61.8)  
 ICS + ICS/LABA 7 (13.0) 7 (20.6)  
OCS 10 (18.5) 3 (8.8)  
 ICS/LABA + OCS 5 (9.3) 1 (2.9)  
 ICS + ICS/LABA + OCS 3 (5.6) 0 (0.0)  
 ICS + OCS 2 (3.7) 2 (5.9)  
  1. Only therapies that were ongoing at baseline and at 6 and 12 months were considered.ICS: inhaled corticosteroids; ICS/LABA: fixed combination of ICS and LABA; LABA: long acting beta2-agonists; OCS: oral corticosteroids
  2. *P-value of Fisher exact test treatment regimen (no ongoing therapies, ICS, OCS) vs gender (females, males) is showed